Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Locus Discovery Incorporated" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Locus Discovery Incorporated for you to read. Along with our medical data and news we also list Locus Discovery Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of Locus Discovery Incorporated Companies for you to search.
MabVax Therapeutics says it doesn’t have enough money to continue funding its operations. The San Diego biotech company, which is testing an antibody discovery platform intended to speed products to patients with cancer and pancreatitis, said Thursday it has retained a local investment banking firm, Objective Capital Partners, to guide its sale. As of Sept. […]
Drug discovery group Evgen Pharma said it was delighted by progress on treatments under development when it announced its interim results for the six months to September 30 today. The AIM-listed business, which has offices in Wilmslow and Liverpool Science Park, focuses on treatments for cancer, strokes and Multiple Sclerosis. It said it released positive interim data from its ongoing clinical stu...
Cellomics Inc. (Pittsburgh) has entered into an agreement with Molecular Probes Inc. (Eugene, OR) that grants Cellomics exclusive rights to key Molecular Probes fluorescence technologies and products for use in Cellomics' high content cell-based drug discovery technologies...
Dr. Spyro Mousses, CEO of Systems Oncology, LLC, announced Systems Oncology’s diversified pipeline of innovative oncology programs discovered with the help of Artificial Intelligence at the AIMed North America Conference in Dana Point, California. Systems Oncology, an AI-based biopharmaceutical company, utilizes computational tools and machine l...
NewsIf approved, it will add to Xarelto's five existing Venous Thromboembolism indications, including treatment of deep vein thrombosis and pulmonary embolism.
goetzpartners securities Limited 14-Dec-2018 / 15:29 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clien...
The Native Antigen Company has launched a series of ground-breaking immunoassays for Zika virus, offering researchers in academia, public health and drug discovery the capability to work with unprecedented levels of specificity and sensitivity. Unlike previous methods, the new assays have little or no cross-reactivity with other flaviviruses, including Dengue, West Nile, Yellow Fever, Japanese Enc...
The York-based Aptamer Group is set to expand its premises after securing $2.2 million in overseas investment in June of this year. The biotech’s expansion will see the company gain two additional laboratories and two additional offices in the York Science Park. The new labs will include a specialist robotics lab and a preclinical discovery lab. read more
Foghorn Therapeutics has appointed Carl Decicco to serve as its chief scientific officer. Decicco joins the Cambridge, MA, biotech from Bristol-Myers Squibb (NYSE: BMY), where he was head of discovery. In addition to his executive role at Foghorn, Decicco will also serve as a venture partner at Flagship Pioneering, the venture capital firm that launched […]
(University of Melbourne) Medical researchers at Melbourne's Murdoch Children's Research Institute have made a new discovery about how a baby's sex is determined -- it's not just about the X-Y chromosomes, but involves a 'regulator' that increases or decreases the activity of genes which decide if we become male or female.
(EMBO) Researchers have uncovered a microRNA cluster that regulates synaptic strength and is involved in the control of social behavior in mammals. The researchers presume that their discovery may point to new therapeutic strategies for the treatment of social deficits in neurodevelopmental disorders such as autism spectrum disorder or schizophrenia. The research is published today in EMBO Reports...
NewsNew understanding of molecular underpinnings points to need for more aggressive treatment and earlier.Contributed Author:&n
A medical procedure transferred a key component of Alzheimer’s disease from one person to another, finds a new study published today in the journal Nature. The discovery suggests the seeds of the devastating neurodegenerative disease are transmissible. “It is a new way of thinking about the condition,” John Collinge, a neurologist at the University of College London in the United Kingdom, w...
ArticleResearchers at The Scripps Research Institute have created monoclonal antibodies that are effective against several synthetic opioids, including fentanyl.
NewsDespite public health efforts, many people who get fungal infections in their blood streams die, even if they can be identified and treated with antifungal drugs.
BiomX’s XMarker microbiome-based biomarker discovery platform to identify responders to a key Janssen IBD therapeutic Ness Ziona, Israel – Dec. 12, 2018 – BiomX Ltd., a microbiome company developing customized phage therapies, today announced that it has entered into a collaboration with Janssen Research & Development, LLC to utilize BiomX’s XMarker microbiome-based biomarker discovery...
Largest-ever Protein Measurement Study Enhances deCODE's Efforts in Basic Research, Drug Discovery and Novel Protein-based DiagnosticsREYKJAVIK, Iceland and BOULDER, Colo., Dec. 13, 2018 /PRNewswire/ -- deCODE genetics, an Amgen subsidiary, and SomaLogic, Inc. today announced a collaboration that brings together SomaLogic's expertise in human proteins with deCODE's expertise in human genetics. The...
NewsDiscovery of atomic-scale binary logic powers faster, more energy-efficient electronics. Contributed Author:
- Scientific and strategic leaders bring significant operating experience to the firm’s company creation mission - Third Rock Ventures LLC today announced that Christoph Lengauer, Ph.D., and Jeffrey Tong, Ph.D., have joined as partners. Both were previously venture partners at the firm. To date, Third Rock has invested in or launched ...
NewsThe collaborative agreement will include early clinical manufacturing of QBM-001 in support of Q BioMed's Autistic Spectrum Disorder drug development program.
— SEP-363856 was identified through a collaboration between Sunovion and PsychoGenics — — Findings provide validation of the PsychoGenics discovery platform — — SEP-363856 holds promise to be the first agent for the treatment of schizophrenia that does not bind to dopamine 2 (D2) receptors —
Biomax Informatics AG announced the launch of its latest product, the NeuroXM™ Brain Science Suite, this week at the Biomax-ETRI Symposium on Cognitive Brain Informatics held in Planegg, Germany. Following a successful early-adaptor program, the company launched the NeuroXM suite of tools and features for working with multimodal high-dimensional brain da...
Biocompare just released its third documentary entitled “What Researchers Need to Know about Antibody Manufacturing”. The goal of this film is to educate scientists about antibody production, validation, and responsible sourcing. SAN FRANCISCO (PRWEB) December 13, 2018 Biocompare, the leading online information resource for the life sciences, just released a must-see documentary entitled “W...
Decicco also to become Venture Partner at Flagship Pioneering Foghorn® Therapeutics Inc. (Foghorn), a discoverer and developer of new medicines based on insights into genetic mutations in the chromatin regulatory system, and Flagship Pioneering, a unique life science innovation enterprise, today announced the appointment of Carl P. Decicco, Ph.D., as ...